SCHEMBL7562222

SCHEMBL7562222

Cc1c(C(=O)NN=Cc2nccs2)[nH]c2c(Cl)cccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.45
LMNA P02545 6/20 0.45
SMN1; SMN2 Q16637 6/20 0.45
THRB P10828 2/20 0.45
MEN1 O00255 10/20 0.44
KMT2A Q03164 10/20 0.44
ALDH1A1 P00352 4/20 0.44
KDM4E B2RXH2 3/20 0.44
GAA P10253 2/20 0.44
HTT P42858 2/20 0.44
RAB9A P51151 5/20 0.41
NPC1 O15118 4/20 0.41
PKM P14618 1/20 0.41
MAPK1 P28482 1/20 0.40
POLB P06746 2/20 0.39
MCL1 Q07820 1/20 0.38
CDK9 P50750 1/20 0.37
DYRK1A Q13627 1/20 0.37
HCRTR1 O43613 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7562221 1.00 MAPT (0.45) MAPTLMNASMN1; SMN2THRBMEN1
SCHEMBL7560052 0.85 MAP2 (0.50) MAPTLMNASMN1; SMN2THRBMEN1
SCHEMBL7560061 0.85 MAP2 (0.50) MAPTLMNASMN1; SMN2THRBMEN1
SCHEMBL7558031 0.83 MAPT (0.53) MAPTLMNASMN1; SMN2THRBMEN1
SCHEMBL7558029 0.83 MAPT (0.53) MAPTLMNASMN1; SMN2THRBMEN1
SCHEMBL7560001 0.79 MAPT (0.65) MAPTLMNASMN1; SMN2THRBMEN1
SCHEMBL7527471 0.79 MAPT (0.65) MAPTLMNASMN1; SMN2THRBMEN1
SCHEMBL7533722 0.77 MAPT (0.54) MAPTLMNASMN1; SMN2THRBMEN1
SCHEMBL7673257 0.77 MAPT (0.54) MAPTLMNASMN1; SMN2THRBMEN1
SCHEMBL7679927 0.76 MAPT (0.62) MAPTLMNASMN1; SMN2THRBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US claimed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO claimed
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US disclosed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors MKI67, FLT4, IDO1 MAPT 4828/4885LMNA 4535/4885SMN1; SMN2 4745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.